Wall Street analyst’s perspective: taking the pulse of the nucleic acid-based prophylactic & therapeutic vaccine sectors

Nucleic Acid Insights 2024; 1(1), 31–36

DOI: 10.18609/nai.2024.006

Published: 23 February
Hartaj Singh

It is a challenging funding environment for all in the biotech world, but just how resilient are the nucleic acids field and its component technology areas such as mRNA and oligonucleotides, comparatively speaking? David McCall, Senior Editor, Nucleic Acid Insights, talks to Hartaj Singh, Managing Director and Senior Analyst, Biotechnology, Oppenheimer & Co., Inc., about the current and future issues, trends, and drivers shaping the prospects of the field.